Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation.
暂无分享,去创建一个
F. Fedele | M. Mancone | G. Sardella | G. Biondi‐Zoccai | S. Calcagno | Carlotta de Carlo | E. Canali | G. Conti | R. Stio | L. Lucisano | Simone Calcagno
[1] P. Damman,et al. Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous™ bio‐engineered R stent™ in patients from the e‐healing registry , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[2] Pierfrancesco Agostoni,et al. Are propensity scores really superior to standard multivariable analysis? , 2011, Contemporary clinical trials.
[3] S. Johnston,et al. Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[4] Yudai Yano,et al. The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. , 2011, Journal of cardiology.
[5] A. Gavazzi,et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. , 2011, The American journal of cardiology.
[6] M. Pencina,et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent , 2010, American heart journal.
[7] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .
[8] S. de Servi,et al. Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-GISE) Italian Multicenter Registry on Bifurcations (I-BIGIS). , 2010, American heart journal.
[9] Q. Fang,et al. [Effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention]. , 2010, Zhonghua yi xue za zhi.
[10] A. Colombo,et al. Prolonged double antiplatelet therapy in a cohort of "de novo" diabetic patients treated with drug-eluting stent implantation. , 2010, The American journal of cardiology.
[11] Nikki M. Carroll,et al. Increased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation: Insights From the HMO Research Network-Stent Registry (HMORN-Stent) , 2010, Circulation. Cardiovascular interventions.
[12] M. Jeong,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.
[13] L. Køber,et al. Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study , 2010, BMC cardiovascular disorders.
[14] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[15] J. Suh,et al. Reasonable duration of Clopidogrel use after drug-eluting stent implantation in Korean patients. , 2009, The American journal of cardiology.
[16] A. Kastrati,et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. , 2009, European heart journal.
[17] E. Mozaffari,et al. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population , 2009, Current medical research and opinion.
[18] K. Harjai,et al. Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry , 2009, Heart.
[19] Deepak L. Bhatt,et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. , 2009, The American journal of medicine.
[20] C. Reid,et al. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. , 2009, American heart journal.
[21] F. Verheugt,et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.
[22] K. Kent,et al. Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. , 2009, American Journal of Cardiology.
[23] Liu Yuyang,et al. Prolonged Dual Antiplatelet Therapy Improves Clinical Outcomes in High‐risk Patients Implanted with Sirolimus‐eluting Stents , 2009, Clinical cardiology.
[24] Y. Hayashi,et al. Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.
[25] Sunil V. Rao,et al. Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. , 2008, American Journal of Cardiology.
[26] M. Pfisterer,et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis , 2008, BMJ : British Medical Journal.
[27] I. Liu,et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. , 2008, Journal of the American College of Cardiology.
[28] P Michael Ho,et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. , 2008, JAMA.
[29] A. Colombo,et al. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. , 2007, The American journal of cardiology.
[30] J. Rumsfeld,et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. , 2007, American heart journal.
[31] Jeroen J. Bax,et al. Universal definition of myocardial infarction. , 2007 .
[32] A. Colombo,et al. Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment , 2007, Circulation.
[33] J. Granada,et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.
[34] David O. Williams,et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. , 2007, JAMA.
[35] C. Di Mario,et al. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study. , 2007, International journal of cardiology.
[36] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[37] S. Pocock,et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.
[38] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[39] P. Serruys,et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[40] C. Grines,et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[41] David B Matchar,et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.
[42] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[43] F. Burzotta,et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. , 2006, European heart journal.
[44] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[45] F. Burzotta,et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. , 2005, American heart journal.
[46] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[47] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.